Status:
NOT_YET_RECRUITING
OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
Lead Sponsor:
Beihua Kong
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore r...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Women over 18 years old;
- Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;
- ECOG \< 2;
- The expected survival period exceeds 6 months;
- CA125 ≤ 35 U/ml before initial treatment;
- Undergo surgery and adjuvant chemotherapy;
- The period between diagnosis and enrollment does not exceed 8 weeks;
- Be willing to provide blood samples for OCS testing during the research process;
- Sign the informed consent form.
- Exclusion criteria
- Have had other malignant tumors within the last five years;
- Have received any treatment for ovarian cancer;
- Benign ovarian mass;
- Non-primary ovarian tumors;
- Combined with other malignant tumors;
- Patients receiving neoadjuvant therapy;
- Pregnancy.
Exclusion
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT07153705
Start Date
September 1 2025
End Date
April 1 2026
Last Update
September 4 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.